Results
1 -
10 of
115The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies, The European Journal of Health Economics DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics, Heart Failure Reviews Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials, Advances in Therapy Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Combination with Metformin, Advances in Therapy Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors, Clinical Pharmacokinetics Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus, Advances in Therapy Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials, European Journal of Clinical Pharmacology Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes, Advances in Therapy Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor, BMC Pharmacology